2 results
Approved WMORecruiting
PART I:Primary:• To investigate the safety and tolerability of two doses of VAD044 administered daily for up to 12 weeks in HHT patients.Secondary:• To assess the effects of two doses of VAD044 for up to 12 weeks of treatment on:o Epistaxis:•…
Approved WMOCompleted
To generate high quality empirical evidence for the effectiveness in terms of proportion of patients experiencing complications, quality of life and costs of initial non-operative treatment strategy (reserving appendectomies for those not responding…